STERIS - STE Stock Forecast, Price & News

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

STERIS Price Performance

Shares of NYSE:STE opened at $213.90 on Friday. The firm has a market capitalization of $21.39 billion, a P/E ratio of 57.35 and a beta of 0.71. The company has a quick ratio of 1.35, a current ratio of 2.03 and a debt-to-equity ratio of 0.44. The stock's 50-day simple moving average is $211.09 and its two-hundred day simple moving average is $224.65. STERIS has a twelve month low of $192.40 and a twelve month high of $255.93.

STERIS (NYSE:STE - Get Rating) last posted its quarterly earnings data on Wednesday, May 11th. The medical equipment provider reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.00 by $0.04. The firm had revenue of $1.21 billion during the quarter, compared to analysts' expectations of $1.18 billion. STERIS had a return on equity of 12.40% and a net margin of 7.90%. As a group, equities analysts anticipate that STERIS will post 8.51 EPS for the current fiscal year.

STERIS Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 23rd. Investors of record on Wednesday, September 7th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 6th. This is a boost from STERIS's previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.88%. STERIS's dividend payout ratio is currently 46.11%.

Analyst Upgrades and Downgrades

STE has been the topic of several analyst reports. Needham & Company LLC cut their target price on STERIS from $248.00 to $237.00 and set a "buy" rating on the stock in a research report on Thursday, August 4th. KeyCorp lowered their target price on STERIS from $256.00 to $240.00 and set an "overweight" rating on the stock in a research note on Thursday, August 4th. StockNews.com upgraded STERIS from a "hold" rating to a "buy" rating in a research note on Thursday. Piper Sandler began coverage on STERIS in a research note on Thursday, July 14th. They issued an "overweight" rating and a $240.00 target price on the stock. Finally, TheStreet upgraded STERIS from a "c+" rating to a "b" rating in a research note on Tuesday, August 2nd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $252.00.

Insider Activity at STERIS

In other news, VP John Adam Zangerle sold 2,659 shares of the stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $205.31, for a total value of $545,919.29. Following the completion of the transaction, the vice president now owns 27,936 shares of the company's stock, valued at approximately $5,735,540.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.14% of the stock is currently owned by company insiders.